REVIEW: Current understanding of the pathogenesis of Fuchs’ endothelial corneal dystrophy

COL8A2-- Multigenerational familial studies discovered the first FECD locus at the chromosomal position 1p34.3–p32.3 (FECD1), where researchers identified pathogenic mutations in the collagen gene COL8A2 (Appendix 1) [26-33]. Mutations positioned in the triple helical domain of α2, p.Leu450Trp and p.Gln455Lys, alter the structure and composition of Descemet’s membrane, leading to the early onset type of FECD [28,29,31]; the latter mutation is present in almost all the early onset cases in English and Korean populations [28,31]. Endothelial guttae, aberrant collagenous deposition, and swollen endoplasmic reticulum (ER) were characteristic of a homozygous mutant (p.Gln455Lys/ p.Gln455Lys) mouse model for early onset FECD [34]. Other mutations identified in different studies were either polymorphic or non-pathogenic [27,29,30]. These studies provided a crucial insight into the phenotypic repercussions on the corneal endothelium of accumulated mutations in COL8A2, and can help devise better preventive measures to curb disease progression. Despite various attempts, researchers have failed to identify any mutations and polymorphisms in the COL8A2 gene among late onset FECD cases, suggesting its genetic involvement is exclusive to early onset cases [27,35].

TCF4-- TCF4, encodes E2–2 protein, a group of E protein transcription factors known for cellular growth and differentiation, and is the only gene studied extensively in FECD cases from various ethnic backgrounds. After performing a GWAS, Baratz and colleagues first identified a strong association between the polymorphic marker rs613872 within an intron of the TCF4 gene and FECD [36]. This association was later confirmed by several replication studies in American [16,37] and Australian [38,39] ethnic populations, but was not polymorphic among Chinese, where two other polymorphisms, rs17089887 and rs17089925, in close linkage disequilibrium (LD) with each other, were found to be associated with FECD [40]. Subsequent studies reported a microsatellite region comprising CTG trinucleotide repeats (TNRs) in the fourth intron of the TCF4 gene to be abnormally expanded and segregated among most patients with FECD. This genetic signature for FECD is most prominent in Caucasians, with 80% penetrance [41,42], followed by Germans (77% [43]), Australians (51% [44]), and Asians (Chinese, 43% [45], and Indians, 34% [46]).

SLC4A11-- FECD shares several phenotypic similarities with other endothelial (posterior) corneal dystrophies, such as congenital hereditary endothelial dystrophy (CHED, OMIM: 121700) and posterior polymorphous corneal dystrophy (PPCD, OMIM: 122000) [47,48]. Therefore, it is convenient to hypothesize that clinical manifestations of these corneal dystrophies may share modifications of similar genes [49,50].

SLC4A11 is the only member of the solute carrier 4 (SLC4) borate transporter family of proteins that conducts Na⁺-coupled H⁺ flux and OH^- transport [51]. Scientists have also reported the active participation of SLC4A11 in water resorption through the basolateral surface of the endothelium to maintain deturgescence [52]. Mutations in this protein result in either a swollen cornea, in the case of corneal dystrophies, such as CHED (OMIM: 217700) [53] and FECD4 (OMIM: 613268) [50,54], or fluid imbalance in the inner ear, in the case of the hearing disorder Harboyan syndrome (OMIM: 217400) [49]. Therefore, it is not surprising to find hearing disabilities in patients with corneal dystrophies [49,55]. In an Indo-Chinese FECD cohort, four likely loss-of-function mutations in SLC4A11 (p.Glu399Lys, p.Gly709Glu, p.Thr754Met, and c.99–100delTC) were uncovered by Vithana et al. [56].

A comparative assay between FECD and CHED-causing SLC4A11 mutants in transformed human embryonic kidney (HEK) cells revealed that FECD mutants (p.Glu399Lys, p.Gly709Glu, and p.Thr754Met) in heterozygous condition drastically reduced the cell surface population of wild-type SLC4A11 proteins. In contrast, the cell surface efficiency of wild-type (WT) SLC4A11 proteins is unaffected by the coexpressing CHED2-causing mutants (p.Glu143Lys, p.Cys386Arg, and p.Arg755Trp) [57]. ER retention of WT/FECD heterodimers explains the dominant nature of FECD. Given the differences, the two diseases also share a similar phenotype when these mutants are expressed homozygously, and the mutant homodimers are intracellularly retained, leading to a severely dysfunctional corneal endothelial pump function. Further studies to strategize methods that can rescue these phenotypes (to an extent) by supplementing wild-type SLC4A11 peptides may help these patients avoid corneal transplantation.

ZEB1-- Similar to SLC4A11, mutations in the transcription factor Zinc finger E- Box binding homeodomain 1 (ZEB1) have been associated by researchers with FECD6 (OMIM: 613270) and posterior polymorphous corneal dystrophy (PPCD3, OMIM: 609141). Nonsense or truncating mutations identified in this gene are a significant contributor for PPCD, which is more severe than FECD [58-61]. As FECD has phenotypic similarities to PPCD, scientists also found missense mutations in FECD case-control studies, some of which were intolerant according to Sorting Intolerant From Tolerant (SIFT) and PolyPhen analysis (Appendix 1). Of these mutations, p.Gln840Pro cosegregated with the FECD7 (OMIM: 613271) locus on chromosome 9 in a multigenerational family, and increased disease severity in 7/12 individuals [58]. These studies suggested that PPCD and FECD could be allelic variants of a continuum of diseases in which genes interact to modulate the expressivity of the phenotype [58].

AGBL1-- ATP/GTP binding protein-like 1 (AGBL1) is a deglutamylase enzyme, which removes polyglutamate residues during post-transcriptional modification of proteins.AGBL1 was identified as a candidate gene during serial analysis of gene expression (SAGE) analysis of FECD tissues where the gene’s transcript levels differed significantly from those of the control specimens [62]. To find a unique genetic candidate for FECD, scientists performed linkage analysis in a multigenerational family, and found a nonsense mutation (p.Arg1028X) in the AGBL1 gene that partially cosegregated with FECD. Upon scanning the entire gene, the authors also found a missense mutation, p.Cys990Ser, unique to the FECD cohort. Both mutations ablated the interaction between AGBL1 and TCF4 proteins [63], the exact nature of which is open for investigation. This study led to identifying the associated genetic loci as FECD8 (OMIM: 615523). AGBL1 also surfaced in the latest GWAS study with a modest association [23]. Due to lack of replication studies in other cohorts that can substantiate the presence of these mutations in FECD-affected individuals, the true contribution of the AGBL1 gene in causing this disease is open for further investigation.

KANK4, LAMC1, and ATP1B1-- In addition to TCF4, a subsequent GWAS conducted by Afshari et al. (with 1,404 European FECD cases and 2,564 age- and race-matched controls) identified three novel loci, rs79742895 (KANK4), rs3768617 (LAMC1), and rs1200114 (ATP1B1) linked with FECD [23]. These corresponding genes aid in maintaining corneal deturgescence by regulating routine fluid transport, intercellular contact, and tissue integrity. Improper functioning of these activities could lead to FECD-like symptoms. Therefore, replication studies in other populations and investigations to explore the genes’ role in the disease pathomechanism are warranted (Appendix 1).

LOXHD1-- The protein encoded by lipoxygenase homology domains 1 (LOXHD1) is involved in sensory perception of sound, and targeting other proteins to the plasma membrane. Therefore, missense mutations affecting the conserved domains lead to a progressive form of auditory defect: autosomal recessive deafness (DFNB77, OMIM: 613079) [64,65]. When scientists investigated the FECD3 locus (previously designated as FECD2) in a multigenerational pedigree, they found a missense mutation in LOXHD1 to be the sole causative factor for the disease phenotype [24]. They further found 15 more unique missense mutations in a larger cohort of 207 unrelated patients with FECD, which were absent in 384 control chromosomes. Three of these mutant proteins (p.Arg157Cys, p.Arg547Cys, and p.Arg751Trp) formed intracellular aggregates in in vitro transformed cells. As the study could not provide one allele in the LOXHD1 gene that cosegregated in the FECD pedigree, replication studies are necessary to associate the variants in this gene with the disease. Therefore, IC3D has not included LOXHD1 as an official genetic candidate in the FECD3 locus.

DMPK-- Expanded repeats in the 3′-untranslated region (UTR) of the dystrophia myotonica-protein kinase (DMPK) gene cause the neurodegenerative disorder myotonic dystrophy type 1 (DM1). Other disorders that are the result of repeat expansions in non-coding regions of associated genes include myotonic dystrophy (DM1 and DM2), fragile X-associated tremor/ataxia syndrome (FXTAS), and C9ORF72 (OMIM: 614260) associated amyotrophic lateral sclerosis and frontotemporal dementia (C9ORF72 ALS/FTD). Owing to FECD’s association with the expanded repeats in TCF4, the disorder is now categorized as a trinucleotide-repeat expansion disorder. In a comorbidity study-type setting, researchers investigated 13 patients with DM1, and reported that 46% also had FECD. This finding indicates that apart from TCF4, individuals with FECD could also harbor expansions elsewhere in genome, in this case, the DMPK gene, thus making it a novel genetic candidate for FECD [25,66]. With further studies, other repercussions of these expansions in non-ocular tissues can be assessed.

Channelopathy and pump dysfunction-- The primary function of the cornea is to maintain deturgescence, which is corneal hydration, thickness, and transparency. The corneal endothelium plays a significant role in carrying out this function; therefore, deterioration of the corneal endothelium can cause the characteristic corneal edema seen in FECD.

Aqueous humor present in the anterior chamber (the space between the cornea and the lens) bathes the cornea with solutes and nutrients, which leaks through the selective barrier of endothelial cells into the avascular cornea [69]. Corneal stroma tends to absorb water, which flows through the endothelium driven by the intraocular pressure. Acting like a hydrogel, the endothelium must strike a balance between water imbibing and pumping out, to avoid stromal swelling. Swelling pressure isotherm maintains this equilibrium [70]. When this isotherm is disturbed, the stroma gorges an unquantified amount of aqueous humor that increases the inter-collagen-fibrillar distance, and causes corneal opacification. A healthy stroma counteracts this uncontrolled swelling by implementing the pump leak system of the endothelium [71]. The presence of active Na-K ATPase pumps on the endothelial surface drains the excess aqueous humor when it senses increased stromal pressure, by lowering osmolarity at the basolateral endothelium [71,72]. A dysfunctional pump and barrier system can disturb the corneal deturgescence, and cause edema. FECD is a case of channelopathy where disease-causing mutations accumulate secondary outcomes where ion channels, such as solute carrier family 4 member 11 (SLC4A11), Na⁺, K⁺ transporting ATPase (Na⁺/K⁺ ATPase), aquaporin 1 (AQP-1), and monocarboxylate transporters (MCTs), either are dysfunctional or are less populated on the cell membrane.

SLC4A11 is a densely populated corneal endothelium (CE) membrane borate pump [52]. Its malfunction has been associated with numerous endothelial dysfunctions, such as CHED [53], FECD [50,57], and sensorineural hearing disorder [73]. The majority of the FECD-associated mutations (p.Glu399Lys, p.Gly709Lys, and p.Thr754Met) in this gene are housed in structurally conserved residues [74], which result in loss of function due to ER retention of these misfolded proteins [75]. Other mutations (Gly709Glu) cause membrane expression of partially functional SLC4A11 [57]. Methylation studies also indicated decreased membrane expression of SLC4A11, due to hypermethylation of its promoter in FECD tissues [76]. It ultimately results in failed transport of Na⁺ coupled OH^- transport [51], and NH3:2H⁺ cotransport [77]. Recent studies have reported that ammonia transported by SLC4A11 is essential for ATP generation via glutaminolysis using the Na⁺/K⁺ ATPase system [78], which, in turn, acts as an accessory energy source for the corneal endothelium. Therefore, stripping off the functional units of this membrane protein puts the endothelium under tremendous pressure that initiates a cascade of downstream pathological effects leading to its apoptosis [79].

Na⁺/K⁺ ATPase is a holoenzyme with two components: subunits α₁ and β₁, present in the basolateral region of the corneal endothelium. Abundant transcripts of the β₁ subunit are necessary to assemble functional enzyme molecules in the ER [80,81]. The β₁ encoding gene, ATP1B1, is genetically associated with FECD [23]. A significant drop in its transcript level showed a steady decline in the Na⁺/K+ ATPase density in late onset FECD endothelial cells [82,83]. In neuronal cell lines, researchers induced nuclear respiratory factor 1 (NRF-1) by administering potassium chloride to successfully restore the expression of Na⁺/K+ ATPase subunits [84]. Topical application of steroids, such as dexamethasone, on corneal endothelial cells also increased the expression and activity of Na⁺/K⁺ ATPase [85]. These molecules can be used as potential pharmacological interventions to improve the condition of energy-deprived endothelial cells of patients with FECD.

Other endothelial pump systems significantly downregulated in FECD tissues are aquaporin AQP-1 [86,87] and the monocarboxylate transporters MCT1 and MCT4 [83]. When epigenetic signatures were studied, researchers found that most of the water transport and fluid transport genes were hypomethylated in their gene bodies in FECD tissues [76]. These reports cumulatively indicated that the FECD condition severely curbs the basic functioning of the endothelium by reducing the expression of channel proteins.

Epithelial to mesenchymal transition-- Corneal endothelial lining and stroma secrete a patterned layer of extracellular matrix (ECM), called Descemet’s membrane. In a healthy infant cornea, banded fibrils on the anterior zone of Descemet’s membrane are the thickest, and apparently, then maintain the thickness [10]. In the case of an endotheliopathic cornea like that in FECD, scientists have reported excessive collagenous and fibrillar deposition [11], which reflects as wart-like excrescences under the slit-lamp microscope [8]. Extensive studies on the structure and composition of Descemet’s membrane in FECD have reported significant upregulation of several ECM components, such as collagen subtypes I, III, and XVI; fibronectin; and agrin [88,89]. The initial pathogenic indication of FECD involves thick deposition of fibronectin, followed by deregulated expression of laminin and type IV collagen in the posterior face of Descemet’s membrane in advanced stages [88].

Although the reason for excessive ECM deposition on Descemet’s membrane is obscure, researchers believe that epithelial-mesenchymal transition (EMT) inducer genes might be responsible. During advanced stages of degeneration, the corneal endothelium undergoes fibroblastic changes, such as abnormal deposition of fibrotic ECM, without changing its endothelial phenotype [90]. Investigations on immortalized FECD lines suggested that increased ZEB1 and Snail1 proteins lead to excessive ECM production through the transforming growth factor beta (TGF-β) pathway. Both proteins mediate EMT in various tissues [91]. After supplementing the immortalized FECD (iFECD) cells with inhibitors for TGF-β type I, researchers could suppress ECM overexpression [92]. There are also reports about the overexpression of TGF-β induced protein (TGF-βIp) and clusterin (CLU) in the corneal endothelium [38,89,93]. These initial insights into progressive alterations in the ECM deposits by the FECD-affected endotheliopathic cornea have broadened our current understanding of the pathology to develop therapeutic targets against it.

RNA toxicity and RAN translation-- The association of TCF4 expansion repeats with FECD has provoked three burning questions among researchers: 1) What is the underlying pathological mechanism? 2) What is the copy number of repeats that cause toxicity? 3) Does the TNR affect TCF4 expression? The pathological outcomes of repeat-expansion diseases can be explained by two distinct mechanisms: the toxicity of RNA repeats and the toxicity of repeat-associated non-ATG (RAN) translation, or a combination of the two. Whether these pathological pathways are coregulated in FECD is still an open-ended question.

The post-transcriptionally processed repeat expansions sequester splice-machinery proteins, such as MBNL1 and MBNL2, which physically appear as RNA foci in FECD cells [25,94,95]. This sequestration alters the concentration of correctly spliced transcripts of their target genes. FECD shares these pathological events with myotonic dystrophy type 1 (DM1) where expanded CTG trinucleotide repeats (present in the 3′-UTR of the DMPK gene) sequester MBNL1 into RNA foci, and cause abnormal RNA processing [96,97]. RNaseq transcriptome analysis performed with FECD and control tissue samples identified 18/24 overlapping transcriptional events with DM1 splicing changes [94]. Further, the reports of the DMPK expansions observed in FECD cases [25,66] have confirmed FECD as a TNR-mediated RNA pathology disorder. Future studies are essential to investigate the impact of the repeat expansions in the DMPK and TCF4 genes on the severity of FECD.

Researchers have performed multiple tests to identify the disease-causing threshold of TNRs in FECD. In the first few studies, an arbitrary limit of 50 TNRs was considered disease-causing. Using fluorescence in situ hybridization (FISH) and multiple cell lines with varying copy number genotypes, researchers have ascertained that >32 TNRs is sufficient to form RNA foci in nuclei [98,99]. However, validating these pathological thresholds in FECD tissues in the future will help provide more insights. Owing to the TNRs’ nature as a master regulator of genes, researchers have also explored the possibility of non-coding TNR expansion to modulate TCF4 expression. They speculated that these non-coding expanded repeats would result in insufficient TCF4 to regulate the expression of essential genes and transcription factors, and cascade down to cause FECD [36,100,101]. However, given the complex transcript variants of TCF4, it is difficult to ascertain the same.

Alternatively, these expanded repetitive stretches of nucleotides elicit RAN translation, in which it allows the ribosomes to translate the expanded repeats in multiple reading frames to produce multiple homopolymeric or dipeptide repeat-containing proteins. The RAN peptides thus produced can disrupt cellular functions by forming nuclear and cytoplasmic inclusions that contribute to disease pathogenesis through various mechanisms, including proteasome impairment, endoplasmic reticulum stress, nucleolar stress, nucleocytoplasmic transport defects, alterations of the nuclear lamina, mis-splicing, mitochondrial dysfunction, and oxidative stress [102-105]. Recent evidence of RAN translation products in FECD-affected corneal tissues having expanded CTG repeats [106] has put FECD in the types of other repeat expansion disorders, such as spinocerebellar ataxia types 8 (SCA8), SCA31, familial forms of amyotrophic lateral sclerosis, frontotemporal dementia, fragile X tremor/ataxia syndrome (FXTAS), Huntington disease (HD), and myotonic dystrophy type 2 (DM2). The toxicity induced by the RNA and protein gain of function mechanism has resulted in these serious neurodegenerative disorders, whereas apart from atrophied corneal endothelial cells, neurodegeneration in FECD has not been reported.

Mitochondrial pathology-- Corneal endothelial cells are metabolically demanding due to the constant flux of ions and fluids; thus, these cells are the most populated with mitochondria in comparison to all other ocular tissues. FECD is a result of heightened oxidative stress in decompensated corneal endothelial cells with an inefficient mitochondrial system [107]. Features pathognomonic of compromised mitochondria in iFECD lines and ex vivo specimens include increased mitochondrial DNA damage, decreased mitochondrial membrane potential, and mitochondrial fragmentation [108,109].

Electron microscopy of the FECD endothelium showed that the remaining mitochondria in the surviving cells were overtaxed, to produce cytochrome oxidase activity products [110]. These mitochondria fail to recover entirely from an external oxidative insult (such as exposure to hydrogen peroxide or menadione) compared to their healthy counterparts [108]. These overburdened mitochondria succumb to mitophagy (mitochondrial fragmentation), owing to decreased Mitofusin-2 (Mfn2) expression, which is necessary to maintain a healthy mitochondrial turnover [109]. The mitochondrial transcripts, essential to curb the increased reactive oxygen species (ROS), are also depleted systematically in FECD [62], which could be a consequence of their hyper-methylated promoters [76].

To salvage the surviving endothelial cells, it is necessary to stop the rapid decline of the mitochondrial mass in these cells. Therefore, researchers are targeting to stabilize cardiolipin (a phospholipid present in the inner mitochondrial wall) to restore ATP production. Elamipretide is a synthetic mitochondria-targeted tetrapeptide (SS-31) that ameliorates mitochondrial dysfunction by preventing peroxidation of cardiolipin [111]. Stealth Biotherapeutics is in Phase II trials to test the efficacy of this drug on patients with FECD (ClinicalTrials.gov Identifier: NCT02653391).

Oxidative stress response and apoptosis-- Due to the localization and function of the cornea, it is regularly exposed to sunlight and atmospheric oxygen, mainly dioxygen, which produce ROS. Oxidative stress response in FECD is a consequence arising from the accumulation of mutations, channelopathy, ER stress, and RNA toxicity. When cells fail to clear the excessive ROS adequately, an imbalance is created in the oxidant–antioxidant level that elevates oxidative stress. Primary cellular scrubbers (antioxidants) that clean oxidative waste products are superoxide dismutases (cytosolic and mitochondrial), catalase, glutathione peroxidase, and glutathione reductase. Their transcript levels are severely low in FECD cases [62]. The transcription factor NRF2 plays a significant role in the expression of these antioxidants during an oxidative insult. When in the cytosol, NRF2 is in the inactive state as the NRF2-KEAP1 complex. Upon oxidation, active NRF2 dissociates and translocates to the nucleus with a transcriptional coactivator and stabilizer molecule, DJ-1 (also known as PARK7; Parkinsonism associated deglycase) [112]. In FECD cells, DJ-1 levels are severely decreased, which, consequently, fail to activate the antioxidant genes [113]. In addition, depletion of SLC4A11 from the cell surface affects cell viability and NRF2 functionality [114]. Targeting these genes to thwart corneal degeneration will be therapeutically beneficial [115,116].

Unfolded protein response (UPR) also elevates oxidative stress in FECD specimens, which is evident from the rough and enlarged endoplasmic reticulum of the endothelial cells [117]. Deregulated transcript levels of UPR markers, such as GRP78 (OMIM: 138120), phospho-eIF2α (OMIM: 609234), CHOP (OMIM: 126337), EDEM3 (OMIM: 610214), SCAP (OMIM: 601510), SEL1L (OMIM: 602329), HSPA5 (OMIM: 138120), and PFDN5 (OMIM: 604899), in the affected tissues further validate this finding [83,117]. Activation of UPR can be due to several reasons: accumulation of misfolded mutant proteins, inefficient anterograde/retrograde transportation, and oxidative imbalance. These processes are the result of genetic or environmental predisposition. Although it is not essential for them to co-occur, individually or in combination, they can cause oxidative stress and apoptosis of the endothelial cells, a feature quite evident in every FECD specimen examined thus far.

In previous sections, how various mutations in the conserved regions of SLC4A11 (failed surface-localization), LOXHD1 (cytoplasmic aggregates formation), and COL8A2 (recreation of early onset FECD phenotype in the knock-in mouse model) lead to FECD phenotype through ER retention was discussed [24,34,56]. Although these mutations share only a limited genetic load to cause FECD, repercussions of UPR are evident in every FECD affected tissue sample. Okumura and colleagues addressed this by reporting an enhanced expression of TGF-β isoforms (TGF-β1 OMIM: 190180 and TGF-β2 OMIM: 190220) and their receptors (TGF-βR1 OMIM: 190181 and TGF-βR2 OMIM: 190182), which chronically overload the ER with ECM proteins (fibronectin and collagen type 1), and consequently, elicit UPR and apoptotic pathways [118]. Targeting these receptors with therapeutic inhibitors to block the TGF-β pathway has suppressed aggresome accumulation and apoptosis in iFECD lines [118].

Oxidative stress in these decompensated endothelial cells tends to accumulate irreparable DNA damage, such as oxidative DNA lesions (8-hydroxy-2′-deoxyguanosine) [107]. Such damage stops the proliferative capacity of these cells, and leads to premature senescence and p53-mediated apoptosis [119]. Reports suggested that cells overexpress clusterin in response to cytotoxic stress in early and late onset FECD [120]. Researchers also speculated that the accumulation of extracellular clusterin and TGF-βIp in cells are likely to scavenge the aberrant ECM to promote intercellular cell-substratum adhesive interactions, and maintain integrity in the disease-stricken decaying tissue [93,121,122].

To summarize, various genetic and environmental stressors accumulate spontaneous mutations over a period. Depending on the site of mutagenesis, they can lead to cell toxicity (aberrant protein folding), nuclear toxicity (RNA foci formation), or deregulation of essential genes involved in maintaining crucial corneal endothelial functions, such as hydration, fluid flux, mitochondria-mediated ATP generation, DNA repair, and antioxidant production. One or several of these events can co-occur, to bring out the pathophysiological etiology of FECD (Figure 1). Understanding the pathomechanism can allow investigators to design symptom-specific therapeutics that can avert or delay the progression of FECD.

Current surgical techniques-- Surgical modifications of endothelial keratoplasty include posterior lamellar keratoplasty (PLK), deep lamellar endothelial keratoplasty (DLEK), (femtosecond) Descemet stripping (automated) endothelial keratoplasty (DSEK/DSAEK/FS-DSEK), and Descemet membrane endothelial keratoplasty (DMEK). DSAEK has been the treatment choice in the past decade for patients with endothelial failure. This technique has decreased the rejection rate, intraoperative and postoperative complications, and astigmatism, and produced faster visual recovery with more consistent results, compared with PK [123-125]. In DMEK, Descemet’s membrane, along with the endothelium, is replaced [126]. This technique has improved outcomes over DSAEK in rejection rates and visual recovery, but is not recommended in all cases of endothelial dysfunction. In addition to these techniques, Descemetorhexis without EK has recently been employed to treat FECD [127-129].

Non-surgical interventions-- Although surgeons have improved on the postoperative challenges, surgical procedures are always physically and mentally arduous, with the patient having to bear the shortcomings in their twilight years. Koizumi and colleagues effaced these surgical pitfalls when they introduced a revolutionary eye drop formula containing a Rho-kinase (ROCK) inhibitor (Y-27632) that completely regenerated the apoptotic and terminally differentiated corneal endothelial cells in monkeys to restore vision [130].

Okumura and colleagues scrapped off the corneal endothelial layer to demonstrate a corneal endothelial dystrophy animal model, and injected cultured monkey corneal endothelial cells (MCEnCs), suspended in culture media supplemented with Y-27632 (ROCK inhibitor), into the anterior chamber. After allowing the cells to settle for 3 h in the face-down anaesthetized monkey, they observed a reattached endothelium through the slit-lamp microscope. When monitored for a year, these healthy endothelial cells restored vision and maintained transparency, without any side effects of the drug in the monkeys. The researchers found similar results for implanting human corneal endothelial cells (HCEnCs) in these primates [131].

After obtaining necessary approval from institutional committees to use Y-27632 in eye drops for treating corneal endothelial dystrophies in humans, the researchers administered this eye drop (6 times daily for 7 days) to a 52-year-old male Japanese patient with advanced FECD [130]. At follow-up after 6 months, the patient showed pronounced improved vision. Although there were no side effects for 2 years, the endothelial cells did not repopulate on the guttae. Randomized clinical trials are necessary before this drug can be used. Even with these reservations, applications of ROCK inhibitor as a potential noninvasive therapy for FECD is promising. ROCK inhibitor (Y-27632) eye drops uplift the mitotic block to regenerate the patient’s endothelial cells in situ. A recent review summarized the potent therapies for FECD [132].

However, if the regenerated endothelial cells develop pathogenic nuclear foci due to expanded TNRs, an unhealthy layer of endothelium will repopulate, which might degenerate over time. Hu and colleagues addressed this issue by administering antisense oligonucleotides against expanded CUG repeats (within TCF4 pre-mRNA) to block RNA foci in patient-derived cells [133]. Post-treatment, these cells significantly reduced the number of RNA foci, and partially restored the alternative splicing events of MBNL1, IN2, and ADD3 genes; however, it remains to be seen whether RNA foci by itself are pathogenic, or bring about their effect through RAN peptides. Both methods, ROCK inhibitor eye drops and antisense oligonucleotides, are promising, noninvasive therapeutic techniques, and it remains to be seen whether if used in combination, they can overcome each other’s limitations.